Anthrax Vaccine Market Forecast Signals New Revenue Opportunities Through 2030
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Anthrax Vaccine Market Revenue Outlook: What CAGR Is Expected Through 2030?
The market for anthrax vaccines has seen consistent expansion in recent times. With a compound annual growth rate (CAGR) of 4.7%, its value is projected to rise from $11.77 billion in 2025 to $12.33 billion in 2026. This historical upswing is driven by several factors, including the widespread occurrence of anthrax among livestock, government-sponsored immunization programs, advances in immunological research, constraints on vaccine manufacturing capabilities, and growing recognition of workplace-related exposure risks.
The market for anthrax vaccines is anticipated to experience consistent expansion over the coming years. By 2030, its value is projected to reach $14.49 billion, reflecting a compound annual growth rate (CAGR) of 4.1%. This forecasted growth is driven by factors such as the creation of recombinant and next-generation vaccines, an increasing need for prophylactic measures in both humans and animals, enhancements in vaccine administration technologies, the broadening of biodefense initiatives, and strengthened partnerships between the pharmaceutical and defense industries. Key trends shaping this period involve the refinement of vaccine compositions, the broadening of immunization schedules, progress in cold chain and storage methods, heightened focus on biodefense and pandemic readiness, and vaccination campaigns led by governments and military organizations.
Download A Free Sample Report For Comprehensive Market Insights:
Anthrax Vaccine Market Growth Momentum: Which Factors Are Influencing Demand?
The growing occurrence of infectious diseases is anticipated to accelerate the expansion of the anthrax vaccine market moving forward. Infectious diseases are conditions caused by harmful microorganisms like bacteria, viruses, parasites, or fungi, capable of being transmitted either directly or indirectly between individuals, with manifestations that can vary from mild to severe and occasionally result in death, influenced by the specific pathogen and the affected person’s immune system. The uptick in infectious diseases stems from shifts in global population demographics, urban expansion, alterations in environmental conditions and land utilization, as well as modifications in human conduct. The anthrax vaccine is mainly employed for protection against anthrax, but its possible broader application in preventing other infectious ailments is being investigated via studies on its immune-boosting traits and flexibility. For example, in February 2023, data from the Council on Foreign Relations, a nonprofit based in the United States, showed that up to 75% of new or emerging infectious diseases and 60% of recognized ones have zoonotic sources. Moreover, worldwide, zoonotic diseases lead to 2.7 million human deaths and 2.5 billion instances of illness in people annually. Consequently, the increasing frequency of diseases is fueling the advancement of the anthrax vaccine market.
Anthrax Vaccine Market Segment Analysis: What Are The Major Market Categories?
The anthrax vaccine market covered in this report is segmented –
1) By Vaccine Type: Cell-Free Protective Antigen (PA) Vaccine, Live Attenuated Vaccine
2) By Application Type: Animal Use, Human Use
3) By Distribution Channel: Hospitals, Pharmacies, Other Distribution Channels
Subsegments:
1) By Cell-Free Protective Antigen (PA) Vaccine: Recombinant Protective Antigen (rPA) Vaccine, Adjuvanted rPA Vaccine
2) By Live Attenuated Vaccine: Live Attenuated Bacillus anthracis Vaccine, Genetically Modified Live Attenuated Vaccine
Anthrax Vaccine Market Trends Reshaping Industry Growth
Key players in the anthrax vaccine market are prioritizing the creation of novel products and obtaining FDA approvals to confirm the safety, efficacy, and accessibility of their vaccines for individuals at risk of anthrax exposure. Authorization from the FDA signifies that the vaccine has undergone rigorous clinical trials and has been validated as safe for public administration, thereby safeguarding people against possible adverse reactions. For example, in July 2023, Emergent BioSolutions Inc., a biopharmaceutical firm based in the United States, secured FDA approval for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), formerly referred to as AV7909. This approval relied on data from a Phase 2 trial that assessed Cyfendus’s lack of interference with antibacterial drugs, alongside Phase 3 research that contrasted its immunogenicity and safety profile with BioThrax, the earlier anthrax vaccine. Additionally, the development of safer and more effective adjuvants is crucial to resolving reactogenicity issues and boosting the overall performance of anthrax vaccines.
Anthrax Vaccine Market Leading Companies Driving Competitive Growth
Major companies operating in the anthrax vaccine market are Emergent BioSolutions Inc., Indian Immunologicals Limited, GC Biopharma, Valneva SE, PharmAthene Inc., Porton Biopharma Limited, Choong Ang Vaccine Laboratories Co. Ltd., Colorado Serum Company Inc., Botswana Vaccine Institute, VECOL S.A., Biological E Limited, Serum Institute of India Pvt. Ltd., Panacea Biotec Ltd., China National Biotec Group, Sinovac Biotech Ltd., Instituto Butantan, Razi Vaccine and Serum Research Institute, Federal State Unitary Enterprise Microgen, KM Biologics Co. Ltd., Haffkine Bio-Pharmaceutical Corporation Ltd.
Access The Complete Anthrax Vaccine Market Report:
Anthrax Vaccine Market Geographic Distribution And Regional Opportunities
North America was the largest region in the anthrax vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anthrax vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
